Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies

Ghadiri-Anari , Akram

doi:10.18502/ssu.v34i6.22664

Volume 34, Issue 6 (9-2026) JSSU 2026, 34(6): 10286-10289 | Back to browse issues page

‎ 10.18502/ssu.v34i6.22664

Mendeley

Zotero

RefWorks

Ghadiri-Anari A. Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies. JSSU 2026; 34 (6) :10286-10289
URL: http://jssu.ssu.ac.ir/article-1-6737-en.html

Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies

Akram Ghadiri-Anari ^*

Keywords: Obesity management, Metabolic surgery, Chronic disease, Public health policy, GLP-1 receptor agonists

Full-Text [PDF 383 kb] (19 Downloads) | Abstract (HTML) (36 Views)

Full-Text: (20 Views)

Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies
Akram Ghadiri-Anari ¹^*
¹ Diabetes Research Center, Non-Communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

		Abstract
* Corresponding author: Diabetes Research Center, Non-Communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Email: ghadiriam@yahoo.com Tel: +983538224000 Postal Code: 8917693571 Received: 19 Jul 2026 Revised: 11 Aug 2026 Accepted: 23 Aug 2026 Citation: Ghadiri-Anari A. Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies. J Shahid Sadoughi Uni Med Sci 2026; 34(6): 10286-289.		Introduction: Obesity represent a complex, chronic, and relapsing medical disorder. The associated global mortality and socioeconomic burden remain considerable worldwide. Innovative pharmacological interventions, such as GLP-1 receptor agonists (e.g., Tirzepatide), have fundamentally changed clinical weight management. Meanwhile, Metabolic surgery remains the most durable option for high risk patients. Consequently, healthcare systems must accept obesity as a chronic disease entity and provide insurance coverage for both medical and surgical treatments to promote equity across public healthcare. Keywords: Obesity management, Metabolic surgery, Chronic disease, public health policy, GLP-1 receptor agonists
This work is licensed under a Creative Commons Att‌ribution 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

References

Bannuru RR, Cefalu WT, Gabbay RA, Calhoun E, Choe HM, Fullerton SM, et al. Introduction and methodology: Standards of Care in Overweight and Obesity-2025. BMJ Open Diabetes Res Care. 2025; 13(Suppl 1): e004928.
World Health Organization. WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. Geneva: World Health Organization; 2025.
Ibrahim M, Ba-Essa EM, Alvarez JA, Baker J, Bruni V, Cahn A, et al. Obesity and its management in primary care setting. J Diabetes Complications. 2025; 39(7): 109045.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-16.
Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2023; 19(1): 3-14.
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021; 397(10271): 293-304.